Biomarker Discovery and Mechanistic Studies of Prostate Cancer using Targeted Proteomic Approaches
Final rept. 1 Jul 2008-30 Jun 2012
KENTUCKY UNIV RESEARCH FOUNDATION LEXINGTON
Pagination or Media Count:
The focus of this collaborative work between Drs. Zhu and Kyprianou has been the identification of EMMPRIN, a cell surface protein we identified to be overexpressed in prostate cancer epithelial cells with a high metastatic potential. Our studies in the funding period have identified the involvement of EMMPRIN in cancer development and progression via controlling extracellular matrix remodeling and anchor-independent growth by stimulating MMP production, angiogenesis via VEGF by activation of AKT-PIK3 pathway, and cell invasion by up-regulation of urokinase-type palsminogen activator. The emerging theme of pursuing the role of EMMPRIN as a functional biomarker in prostate cancer metastasis is being tested in the last year of the funding period. The results have also led us to determine the status of additional proteins that control the actin-cytoskeleton organization such as cofilin.
- Anatomy and Physiology
- Medicine and Medical Research